Navigation Links
Synvista Therapeutics Appoints William Federici to its Board of Directors
Date:10/10/2008

ople with diabetes. The Company has developed a clinical diagnostic test for Hp2-2 Diabetes, a disease affecting almost 7 million patients in the United States. The genetic or protein form of this test can be used to identify diabetic patients at high risk for cardiovascular complications. These patients may benefit from a particular formulation of vitamin E. The Company is also developing a kit to measure CML (carboxy-methyllysine), another potential cardiovascular risk marker.

Synvista Therapeutics is developing oral antioxidant drugs to treat the HDL dysfunction seen in Hp2-2 Diabetes. The Company is also developing alagebrium, a proposed breaker of advanced glycation endproducts (AGEs) for the treatment of systolic and diastolic heart failure. Diastolic heart failure represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable human safety database.

For more information, please visit the Company's Web site at http://www.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics' diagnostic tests and product candidates, and other risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics' Ann
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Synvista Therapeutics to Present at the Roth 20th Annual OC Growth Stock Conference
2. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
3. LaVoie Group Adds Cancer Therapeutics Company, Neotropix(R),to Its Life Science Agency Roster
4. Cell Therapeutics Regains Compliance with NASDAQs Minimum Bid Price Requirement
5. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase Up to $18 Million of Senior Convertible Notes
6. Ikaria(R) Acquires North American Rights to LUCASSIN(R) From Orphan Therapeutics
7. Afid Therapeutics Inc.s New Anticoagulant Heparin Replacement Passes in Vivo Test
8. Industry Experts and Global Regulators to Discuss Oligonucleotide-Based Therapeutics Issues
9. Duska Therapeutics Receives Comments From FDA on Phase 3 ATPace(TM) Protocol Synopsis
10. TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results
11. Clinical Research Management gets contract for trials of therapeutics against infectious diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... New York (PRWEB) April 24, 2015 ... to move forward in the federal multidistrict litigation ... Carolina. According to court documents, the parties involved ... on April 16th detailing, among other things, preparation ... notes that counsel for both plaintiffs and defendants ...
(Date:4/24/2015)... 24, 2015 The first step to ... mind. , For meditation and yoga teacher Stine Koppernæs, ... been invaluable tools that allow her to experience more ... has been a teacher since 2006, and through the ... state of being. , “I love sharing this way ...
(Date:4/24/2015)... 24, 2015 Anchor Health Administrators (Anchor), ... Professionals, today announced their exclusive agreement with LTC Solutions ... Care Insurance distribution partner. , Anchor has more than ... Insurance benefits for associations, and is currently the designated ... Long Term Care Insurance member benefit. , “I am ...
(Date:4/24/2015)... Fla. (PRWEB) April 24, 2015 “Kind,” ... healer” were among the ways Denise Weiner described pediatric ... who cared for her daughter, Alexa, during her five-year ... brain resections, a bone marrow transplant and numerous experimental ... house to visit Alexa when she was not in ...
(Date:4/24/2015)... National Access Cannabis (NAC), Canada’s ... medical cannabis, is taking a leadership role in ensuring ... , NAC is the first to back mdBriefCase Group ... NAC will be providing 300 healthcare professionals with free ... help Canadians gain safe and responsible access to medical ...
Breaking Medicine News(10 mins):Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 3Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 2Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 3Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 4Health News:National Access Cannabis Gives 300 Canadian Healthcare Professionals Access to Medical Cannabis Certificate Program 2
... Awareness,Week approaches, 2009 brings yet another year of unhealthy ... Americans, including men and,boys. , ... eating,disorders is so important because hundreds of thousands of ... even consider an eating,disorder as a diagnosis for a ...
... and ,e-commerce feature to company Web site - www.geritrex.com . ... ... -- The Geritrex Corporation, a privately held pharmaceutical company that offers ... business. Founded by CEO and registered pharmacist Anthony Madaio, Geritrex ...
... tests for devastating conditions, report says , , WEDNESDAY, Feb. 18 ... three babies in the United States was born in a ... of conditions. But by the end of 2008, all 50 ... rules requiring newborn screening for at least 21 disorders, a ...
... RIVER, N.Y., Feb. 18 Tesia-PCI has successfully ... with United Concordia Companies, Inc., a national dental ... took just over two months from plan to ... experience and expertise helped United Concordia to avoid ...
... was announced today that,Medizone International,s (Pink Sheets: MZEI) ... direction of Dr. Michael E.,Shannon of the Canadian ... President of the Canadian Foundation for Global Health. ... Medizone International and is the Company,s,Director of Medical ...
... continues to present its myriad of challenges, SunStone ... cost cutting measures including cutbacks in capital projects, ... direct patient contact such as marketing, community, and ... easier layers to peel in these expense reduction ...
Cached Medicine News:Health News:Remuda Ranch Seeks to Increase Awareness of Eating Disorders Among Males During National Eating Disorders Awareness Week (NEDAW), February 22-28, 2009 2Health News:A "Healthy" Company - Geritrex Celebrates Its 30 Year Anniversary with New Rebranding Effort and Expanding Distribution Channels 2Health News:Newborn Screenings Now Required Across U.S. 2Health News:Newborn Screenings Now Required Across U.S. 3Health News:National Dental Insurer United Concordia Successfully Launches Real-Time Claims Processing with Tesia-PCI 2Health News:The Canadian Foundation for Global Health Announces a Research and Development Partnership with Medizone International, Inc. 2Health News:The Canadian Foundation for Global Health Announces a Research and Development Partnership with Medizone International, Inc. 3Health News:The Marketing Enigma 2
(Date:4/24/2015)... PHILADELPHIA , April 24, 2015  Lannett Company, ... has amended and increased its five-year revolving credit facility ... includes an accordion feature that will allow the company ... an additional $30.0 million, subject to securing additional commitments ... date of the credit facility remains December 18, 2018. ...
(Date:4/23/2015)... 24, 2015  AbbVie (NYSE: ABBV ) has ... has accepted its New Drug Application (NDA) and granted ... antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin ... with chronic genotype 4 (GT4) hepatitis C virus (HCV) ... interferon-free therapy being evaluated by the FDA for patients ...
(Date:4/23/2015)... Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that ... on Thursday, May 7, 2015, after the close of ... audio webcast immediately following the announcement at 4:30 p.m. ... results and provide a business and financial update. ... via the Investors & Media section of the Jazz ...
Breaking Medicine Technology:Lannett Expands Revolving Credit Facility To $120 Million 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7Jazz Pharmaceuticals to Report 2015 First Quarter Financial Results on May 7, 2015 2
... 2010 TechniScan, Inc. (OTC Bulletin Board: ... development and commercialization of an automated breast ultrasound imaging system, ... TechniScan entered into amendments with each note holder, effective as ... its entire portfolio of secured convertible promissory notes from October ...
... 8, 2010 Arstasis is pleased to announce that ... Registry Evaluating Closure Following Access with the Arstasis One ... anticipated to enroll up to 500 patients in at ... is to observe the clinical safety and effectiveness of ...
Cached Medicine Technology:TechniScan, Inc. Announces Restructuring of Convertible Debt 2Seven U.S. Medical Centers Commence Study to Change Femoral Artery Cath Lab Access with the First Alternative to the Seldinger Technique in 51 Years 2Seven U.S. Medical Centers Commence Study to Change Femoral Artery Cath Lab Access with the First Alternative to the Seldinger Technique in 51 Years 3
Straight tips with fine 1 x 2 teeth. Serrated handle with polished finish. Most popular size or model....
Three 2 mm prongs with 0.1 mm angled tips. 20 gauge (.89 mm) diameter shaft. Lightweight Wilson style squeeze handle with dull finish. Most popular size or model....
Straight shafts with 1 x 2 teeth. Flat handle with polished finish....
Straight shafts with 45 degrees, 0.12 mm, 2 x 3 teeth and tying platform. Serrated handle with polished finish....
Medicine Products: